Parkinson's Disease

Genetically Engineered Fibroblast Implants May Lead to New Treatment

Published in Gene Therapy Weekly, January 18th, 2001

Neurologists with the U.S. Veterans Affairs Healthcare System have shown that Parkinson's-type brain lesions can be prevented by the implantation of fibroblasts genetically designed to secrete a protective substance.

C. Shults and colleagues working at the Veterans Affairs Medical Center in La Jolla, California, pursued their thought "that fibroblasts, which had been genetically engineered to produce fibroblast growth factor-2 (FGF-2), can protect nigrostriatal dopaminergic neurons" by conducting a study in rats. They researchers compared the protective effects of fibroblasts engineered to produce FGF-2 and the enzyme beta-galactosidase (beta-gal) ("Fibroblast growth...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry